Digital Diabetes Management Market

Digital Diabetes Management Market by Product (Device (Smart Glucometer, CGM, Insulin Patch Pump), Diabetes Apps, Service, Data Management Software), Device Type (Handheld & Wearables), End User (Hospitals & Self/home healthcare) - Global Forecast to 2027

Report Code: MD 6871 Apr, 2022, by marketsandmarkets.com

[234 Pages Report] The global digital diabetes management market is projected to reach USD 25.5 billion by 2027 from an estimated USD 14.3 billion in 2022, at a CAGR of 12.2% during the forecast period. The rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care. Also, advancements in technologies have ensured the introduction of highly flexible solutions in the market. The increasing adoption of cloud-based enterprise solutions and the growing use of connected devices and apps are some of the other major factors supporting market growth. However, factors such as the high device costs, lack of reimbursement in developing countries, and the higher acceptance of traditional diabetes management devices are expected to restrain the growth of this market during the forecast period.

Digital Diabetes Management Market

To know about the assumptions considered for the study, Request for Free Sample Report

Impact of Covid-19 on Digital Diabetes Management Market

To assess the impact of COVID-19 and provide market forecasts, scenario-based approaches are considered.

In the optimistic scenario, it could be assumed that the COVID-19 pandemic would create a long-term positive impact on the overall digital diabetes management market. The digital diabetes management market was initially negatively impacted by the COVID-19 pandemic, as most hospitals & specialty diabetes clinics and academic & research institutes were closed in many parts of the world due to lockdowns and quarantine restrictions in early 2020. This resulted in all non-essential procedures being deferred; the volume of outpatient cases reduced considerably in this period. Once lockdown and quarantine measures were lifted in most parts of the world, the patient flow was lower as most individuals hesitated to engage in close-contact treatment. However, recovery can be seen in most regions, especially North America and Europe, as services regain normalcy. The Asia Pacific market has been slower to recover, especially in China and India. However, the drivers that had propelled the digital diabetes market previously, such as the rising digitization and the expansion of healthcare infrastructure, are still in place. This can be expected to promote the growth of the market in 2021–2022. In an optimistic scenario, the need for smoother workflows and faster turnaround times could boost the market growth.

In the pessimistic scenario, it could be assumed that the economic impact of the COVID-19 pandemic on the market could affect the adoption of digital diabetes management due to its high capital and operational costs. However, this is unlikely, as market recovery is already seen in most regions at present.

In the realistic scenario, it could be assumed that the long-term effect of the COVID-19 pandemic on the digital diabetes management market is neutral, growing slowly from Q3 2020 and going back to pre-COVID conditions from Q1 2021 onward.

Digital Diabetes Management Market Dynamics:

Drivers : Increasing prevalence of diabetes

According to the WHO, diabetes is expected to become the seventh-leading cause of death by 2030. The major risk factors for diabetes include stress, sedentary lifestyles, unhealthy diets, and obesity. Aging-related physiological changes are also a significant contributor to the risk of diabetes. For instance, according to the International Diabetes Federation, diabetes prevalence increases with age. Thus, the highest estimated prevalence is in people older than 65 years.

Diabetes estimates for 2021 show an increasing prevalence of diabetes by age. Similar trends are estimated for 2045. Diabetes prevalence is lowest among adults aged 20–24 years (2.2% in 2021). Among adults aged 75–79 years, diabetes prevalence is estimated to be 24.0% as of 2021 and is estimated to increase to 24.7% by 2045. These data point to a significant increase in the diabetes population in countries with large geriatric populations in the next 25 years. Therefore, the growing geriatric population, coupled with the increasing population exposure to key risk factors, is expected to drive the demand for digital diabetes management solutions across major markets.

Technological advancements

In the last decade, the medical devices sector has witnessed significant technological advancements in the field of diabetes care, including the emergence of focused sensor-based CGM technology, implantable digital diabetes management devices, closed-loop systems, and wearable smartphone-based diabetes management devices. Technologically advanced systems have improved the ability to manage diabetes and made it practical to achieve tight control while providing a more flexible schedule and diet for patients, children, and their families. Several digital diabetes management solutions currently available are competitive compared to their conventional counterparts, such as prefilled syringes, glucose meter analogs, test strips, and insulin pumps.

Newer digital solutions are being introduced that are more convenient than traditional diabetes management therapies or even previous iterations or counterparts. With the launch of the FreeStyle Libre and Dexcom G5 CGM, for example, devices are facilitating minimally invasive and accurate glucose monitoring. Non-invasive connected sensor developments have been vital in increasing the accuracy of monitoring blood glucose levels and the longevity of the CGM device, as in the case of Eversense XL by Sensionics (that can last up to 180 days). Similarly, skin patches, gas sensors, radio-wave technology, and microneedles are used as minimally invasive methods.

Combination and integrated approaches for the monitoring and management of diabetes are gaining in popularity, apart from standalone devices. These devices can not only provide remote monitoring but also help in providing connected care that is continuous, modular, and targeted. Besides this, smart contact lenses integrated with biosensors and drug delivery materials are being researched for use in CGM, as well as to treat diabetic retinopathy.

Growing adoption of cloud-based enterprise solutions for diabetes management

Improving connectivity and computing power have considerably increased the reach—while decreasing the cost—of medical data sharing, enabling significantly higher levels of patient communication and treatment decision support. Automated uploads through the cloud minimize effort on the part of patients and clinicians, enabling universal, real-time access to data.

In terms of diabetes management, the adoption of cloud-based solutions allows for near-constant monitoring of blood glucose levels; data can be stored safely in the cloud and easily retrieved. Physicians can also view and maintain the patient’s history and test results and prescribe medication through mail or mobile messages based on the latest blood glucose levels. This reduces the burden on healthcare providers and leads to more efficient disease management. With automated transfer to apps and online diabetes data management software, glucose data is made easily accessible during appointments.

Some cloud-based enterprise solutions for diabetes management include Rimidi by Rimidi Diabetes Inc. (US), GlucoMe solution by GlucoMe (Israel), iGlucoCheck by ALTEN Calsoft Labs (US), Diamond by Hicom (UK), One Drop by Informed Data Systems Inc. (US), and eGMS by Glytec LLC (US).

Use of artificial intelligence in diabetes care devices

Artificial intelligence (AI) is a fast-growing field, and its applications in diabetes have reformed the approach to the diagnosis and management of this chronic condition. Principles of machine learning have been used to build algorithms to support predictive models for the risk of developing diabetes or its consequent complications.

Digital therapeutics have proven to be an established intervention for lifestyle therapy in the management of diabetes. Patients are increasingly being empowered for the self-management of diabetes, and both patients and healthcare professionals are benefitting from clinical decision support. AI allows continuous and burden-free remote monitoring of patients’ symptoms and biomarkers. Furthermore, social media and online communities enhance patient engagement in diabetes care.

Technical advances have helped to optimize resource use in diabetes. Together, these intelligent technical reforms have produced better glycemic control with reductions in fasting and postprandial glucose levels, glucose excursions, and glycosylated hemoglobin. AI will introduce a paradigm shift in diabetes care from conventional management strategies to building targeted data-driven precision care. Livongo Health (US), for example, is using a big-data-enabled approach to help people manage their health and improve their lifestyles. Several people are using the company’s innovative products, including blood glucose meters, blood pressure cuffs, and scales, which have the ability to collect data and send it to a larger database. This data is subsequently used by the company to generate comprehensive insights for the benefit of patients.

Restraints : High cost of devices and lack of reimbursement in developing countries

The cost of insulin delivery devices, such as smartphone-connected insulin pumps, is ~USD 4,500–6,500. Moreover, the average selling price of sensor-based continuous glucose monitors is USD 1,000–1,400, with sensors requiring replacement every few days. Digital self-monitoring blood glucose meters cost around USD 15–20. Given the high initial cost and the frequent use of associated consumables (requiring repeated purchase), this puts advanced devices out of reach for a large portion of end users—particularly those in developing countries with an unfavorable reimbursement scenario.

In developed countries, the cost of currently marketed devices is covered under most commercial health plans; in developing countries, disparities in reimbursement policies often result in non-compliance to treatment. In China and India, patients with diabetes are required to entirely bear the expenses for blood glucose monitors, insulin, integrated CGM systems, and their maintenance. Consequently, the high costs and lack of reimbursements in developing countries can be expected to limit the adoption of digital diabetes management solutions in the coming years.

Higher acceptance of traditional diabetes management devices

Patients in many geographical areas still prefer traditional ways to manage diabetes. There are many patients that avoid digital platforms and prefer traditional blood glucose readers and glucose strips, insulin injections, prefilled syringes, and drug therapy due to their low cost and a lack of knowledge about connected devices and apps. The low adoption of smartphones, tablets, and computers for diabetes management in some countries has also affected the acceptance of advanced technologies.

Most available apps and platforms are not being used by elderly patients, non-English speakers, and the physically challenged. This is particularly evident in Asia Pacific, Middle Eastern, and African countries, where low awareness, lack of trained personnel, and unfavorable/negligible reimbursements have affected the use of digital diabetes management. In China and India, reliance on alternative traditional diabetes management practices, such as herbal medicines, is also restraining the market growth.

Opportunities : Increasing diabetes-related health expenditure

The increase in global health expenditure due to diabetes has been considerable, growing from USD 232 billion in 2007 to USD 966 billion in 2021 for adults aged 20–79 years. This represents a 316% increase over 15 years. Part of this increase can be attributed to improved data quality. The direct costs of diabetes are expected to continue to grow. The IDF estimates that total diabetes-related health expenditure will reach USD 1.03 trillion by 2030 and USD 1.05 trillion by 2045 (Source: IDF Atlas 2021). The North America and Caribbean region has the highest diabetes-related health expenditure per adult with diabetes (USD 8,209), followed by the Europe region (USD 3,086), South and Central America region (USD 2,190), and WP region (USD 1,204). This figure is USD 465 per person with diabetes in the Middle East and North Africa region, USD 547 in the Africa region, and USD 112 in the Southeast Asia region. Expenditure due to diabetes has a substantial impact on total health expenditure worldwide, representing 11.5% of the total global health spending. Considering the increasing diabetes-related health expenditure in emerging countries, many digital diabetes management device manufacturers are focusing on expanding their business in these markets to capitalize on new opportunities.

Challenges: Low penetration in developing economies

The penetration of technologically advanced digital diabetes management platforms is comparatively less in developing countries as opposed to developed countries. This is attributed to the inadequate infrastructure, unclear nationwide e-health agendas, the need to overcome public uncertainty over data privacy and security, difficulties in achieving interoperability, lack of a trained workforce in health informatics (and existing initiatives for its development), and fewer strategies to achieve regional integration.

In developing countries, low levels of private and public financial resources are spent on health, which affects access to healthcare as well as the quality of the health system. According to a WHO and World Bank report, as of 2021, 480 million people do not have access to essential health services (mostly in Africa and South Asia). Poor access and quality and low levels of digitization have negative implications on not only key health outcomes but also the poverty rate. The result is a general reluctance and inability to fully adopt advanced solutions, including those for digital diabetes management.

Lack of data security

Security concerns related to proprietary data and applications are considered a major hindrance to the growth of the digital diabetes management market. Since digital diabetes management is an emerging market, there are no standard frameworks to secure the data stored and shared using diabetes care apps and platforms. One of the major risks of using diabetes care apps is the theft of Protected Health Information (PHI), such as health insurance data, by third parties who can commit healthcare fraud using confidential information. On the other hand, several organizations do not possess the resources required to secure these technologies.

Since mobile phones play a critical role in such smart applications and platforms, the simple loss or theft of a mobile device loaded with unencrypted patient data can result in a security breach with serious consequences. In the US, such privacy breaches could lead to enforcement actions by the Department of Health and Human Services (HHS) under the Health Insurance Portability and Accountability Act (HIPAA). Many countries across the globe also have national or regional regulations against data breaches and healthcare frauds. Consequently, although digital diabetes management solutions offer various advantages, the associated security issues may slow the adoption of mobile technology in diabetes management..

“Continuous Glucose Monitoring (CGM) systems segment to grow at the highest CAGR during the forecast period.”

Various products and services considered in the digital diabetes management market are devices, apps, data management software & platforms, and services. The devices segment consist of smart glucose meters, continuous glucose monitoring (CGM) systems, smart insulin pens, and smart insulin pumps/closed-loop systems & smart insulin patches. Similarly, the apps segment is further classified into diabetes & blood glucose tracking apps and obesity & diet management apps. The continuous glucose monitoring systems market is expected to grow at the highest CAGR during the forecast period. This is mainly because these systems are minimally invasive as compared to conventional blood glucose meters.

“Wearable devices segment held the largest share in the Digital Diabetes Management market in 2021.”

Based on type, the digital diabetes management devices market is segmented into handheld devices and wearable devices. Wearable devices accounted for the largest share of 60.3% of the digital diabetes management devices market in 2021. These devices include CGM systems, smart insulin pumps, and smart insulin patches. Increasing awareness about glucose monitoring; the increasing number of regulatory approvals for CGM systems; technological advancements such as closed-loop pump systems, smart insulin patches, and other pipeline devices are some of the major factors propelling the demand for wearable devices for diabetes management. Also, connected devices provide instant access to glucose-level readings at periodic intervals, enable dose management and recording, and allow patients to upload data online at home.

“The Self/home healthcare segment to grow at the fastest CAGR during the forecast period”

The major end users of the digital diabetes management market are self/home healthcare, hospitals & specialty diabetes clinics, and academic & research institutes. The self/home healthcare segment is projected to grow at the highest CAGR of 13.2% during the forecast period. Technological advancements in self/home care digital diabetes management systems and platforms have made them more accurate, minimally invasive, and easy to use. The introduction of CGM systems, insulin pump therapy, applications, and services has increased the demand for non-invasive or minimally invasive systems in home care.

“North America accounted for the largest share of the Digital Diabetes Management market, followed by Europe in 2021”

In 2021, North America accounted for the largest market share of 41.4%, followed by Europe with a share of 29.0%. Also, the U.S accounted for the largest share of 91.8% of the North American digital diabetes management market in 2021. This is attributed to the increasing prevalence of diabetes, technological advancements in digital diabetes management solutions, increasing number of smartphone users in the country, high penetration of digital platforms, growing adoption of cloud-based enterprise solutions for diabetes management, increasing utilization of connected devices and apps for diabetes management, and the growing focus on improving the quality of care delivered to patients.

Geographic Snapshot: Digital Diabetes Management Market

Rotator Cuff Injury Treatment  Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players :

The prominent players operating in the global digital diabetes management market are Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), One Drop (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Decide Clinical Software GmbH (Austria), Pendiq GmbH (Germany), and BeatO (India).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

:

Report Metric

Details

Market Size Available for Years

2020–2027

Base Year Considered

2021

Forecast Period

2022–2027

Forecast Unit

Value (USD Billion)

Segments Covered

By Product & Services, Type, End User and Region

Countries Covered

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Companies Covered

Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), Tandem Diabetes Care (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), One Drop (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Decide Clinical Software GmbH (Austria), Pendiq GmbH (Germany), and BeatO (India) among others.

The research report categorizes digital diabetes management market into the following segments and sub-segments:

By Product & Service

  • Devices
    • Smart Glucose Meters
    • Continuous Glucose Monitoring (CGM) Systems
    • Smart Insulin Pens
    • Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
  • Application
    • Diabetes & Blood Glucose Tracking Apps
    • Obesity & Diet Management Apps
  • Data Management Software & Platforms
  • Services

By Device Type

  • Handheld Devices
  • Wearable Devices

By End User

  • Self/Home Healthcare
  • Hospitals & Specialty Diabetes Clinics
  • Academic & Research Institutes

By Country

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa

Recent Developments:

  • In April 2022, Dexcom launched Dexcom ONE device. The company launched the new Dexcom ONE Continuous Glucose Monitoring System in the UK.
  • In October 2021, LifeScan, Inc. (US) launched OneTouch Solutions. This is a holistic digital health offering linking people with diabetes to solutions and support from proven experts.
  • In September 2020, Roche Diagnostics (Switzerland) launched a remote patient monitoring solution, which is a new element of the RocheDiabetes Care Platform and uses its pattern detection feature.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 31)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                               FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):  BY COMPANY TYPE, DESIGNATION, AND REGION
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):  BY END USER AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
           FIGURE 6 MARKET SIZE ESTIMATION: COMPANY-WISE REVENUE SHARE ANALYSIS (2021)
           FIGURE 7 SUPPLY-SIDE ANALYSIS: DIGITAL DIABETES MANAGEMENT MARKET (2021)
           FIGURE 8 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE DIGITAL DIABETES MANAGEMENT MARKET
           FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE DIGITAL DIABETES MANAGEMENT MARKET
           FIGURE 10 TOP-DOWN APPROACH: GLOBAL DIGITAL DIABETES MANAGEMENT MARKET
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 49)
    FIGURE 12 DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2022 VS. 2027 (USD MILLION)
    FIGURE 14 DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 DIGITAL DIABETES MANAGEMENT MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 DIGITAL DIABETES MANAGEMENT MARKET OVERVIEW
           FIGURE 18 INCREASING PREVALENCE OF DIABETES AND GROWING DEMAND FOR DIGITAL SOLUTIONS ARE DRIVING MARKET GROWTH
    4.2 ASIA PACIFIC: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE AND COUNTRY (2021)
           FIGURE 19 DEVICES SEGMENT TO ACCOUNT FOR THE LARGEST SHARE IN THE ASIA PACIFIC MARKET
    4.3 DIGITAL DIABETES MANAGEMENT MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
           FIGURE 20 THE US MARKET IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.4 REGIONAL MIX: DIGITAL DIABETES MANAGEMENT MARKET
           FIGURE 21 NORTH AMERICAN MARKET TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.5 DIGITAL DIABETES MANAGEMENT MARKET: DEVELOPING  VS. DEVELOPED MARKETS, 2022 VS. 2027 (USD MILLION)
           FIGURE 22 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 23 DIGITAL DIABETES MANAGEMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of diabetes
                               TABLE 2 TOP FIVE COUNTRIES WITH THE HIGHEST NUMBER OF DIABETICS (20–79 YEARS),  2021 VS. 2045
                    5.2.1.2 Technological advancements
                    5.2.1.3 Growing adoption of cloud-based enterprise solutions for diabetes management
                    5.2.1.4 Use of artificial intelligence in diabetes care devices
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of devices and lack of reimbursement in developing countries
                    5.2.2.2 Higher acceptance of traditional diabetes management devices
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing diabetes-related health expenditure
           5.2.4 CHALLENGES
                    5.2.4.1 Low penetration in developing economies
                    5.2.4.2 Lack of data security
    5.3 PORTER’S FIVE FORCES ANALYSIS
           TABLE 3 DIGITAL DIABETES MANAGEMENT MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 PATENT ANALYSIS
           5.4.1 PATENT PUBLICATION TRENDS FOR DIGITAL DIABETES MANAGEMENT
           5.4.2 TOP APPLICANTS (COMPANIES) FOR DIGITAL DIABETES MANAGEMENT PATENTS
                    FIGURE 24 TOP APPLICANT COMPANIES FOR DIGITAL DIABETES MANAGEMENT PATENTS, 2016–2021
           5.4.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR DIGITAL DIABETES MANAGEMENT PATENTS
                    FIGURE 25 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL DIABETES MANAGEMENT PATENTS, 2016–2021
    5.5 TECHNOLOGY ANALYSIS
    5.6 AVERAGE SELLING PRICE TRENDS
           TABLE 4 AVERAGE SELLING PRICE OF SMARTPHONE-CONNECTED INSULIN PUMPS, BY REGION, 2021
           TABLE 5 AVERAGE SELLING PRICE OF SENSOR-BASED CONTINUOUS GLUCOSE MONITORS,  BY REGION, 2021
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 26 DIGITAL DIABETES MANAGEMENT MARKET: VALUE CHAIN ANALYSIS (2021)
    5.8 ECOSYSTEM MAP
           FIGURE 27 DIGITAL DIABETES MANAGEMENT MARKET: ECOSYSTEM MAP (2021)
    5.9 KEY CONFERENCES & EVENTS IN 2022–2023
           TABLE 6 DIGITAL DIABETES MANAGEMENT MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.10 INDUSTRY TRENDS
           5.10.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
                    TABLE 7 HYBRID CLOSED-LOOP SYSTEMS: CURRENT MARKET SCENARIO
           5.10.2 GROWING NUMBER OF COLLABORATIONS BETWEEN STAKEHOLDERS
                    TABLE 8 RECENT COLLABORATIONS IN THE DIGITAL DIABETES MANAGEMENT MARKET
           5.10.3 INCREASING DEMAND FOR FLASH GLUCOSE MONITORING  (FGM) SYSTEMS
    5.11 REGULATORY ANALYSIS
                    TABLE 9 INDICATIVE LIST OF REGULATORY AUTHORITIES
           5.11.1 NORTH AMERICA
                    5.11.1.1 US
                               TABLE 10 US: TIME, COST, AND COMPLEXITY OF THE REGISTRATION PROCESS
                               FIGURE 28 FDA 510(K) APPROVAL PROCESS
                    5.11.1.2 Canada
                               TABLE 11 CANADA: TIME, COST, AND COMPLEXITY OF THE REGISTRATION PROCESS
           5.11.2 EUROPE
                    FIGURE 29 CE MARK APPROVAL PROCESS FOR DIGITAL DIABETES MANAGEMENT SOLUTIONS
           5.11.3 ASIA PACIFIC
                    5.11.3.1 Australia
                    5.11.3.2 Japan
                               TABLE 12 CLASSIFICATION OF MEDICAL DEVICES AND THE REVIEWING BODY IN JAPAN
                    5.11.3.3 China
                               TABLE 13 CHINA: TIME, COST, AND COMPLEXITY OF THE REGISTRATION PROCESS
                    5.11.3.4 India
           5.11.4 LATIN AMERICA
    5.12 REIMBURSEMENT SCENARIO
                    TABLE 14 DIGITAL DIABETES MANAGEMENT PRODUCTS: GLOBAL COVERAGE AND REIMBURSEMENT
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 30 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
                    TABLE 15 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR TOP 3 APPLICATIONS (%)
           5.13.2 BUYING CRITERIA
                    FIGURE 31 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
                    TABLE 16 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
    5.14 ASSESSMENT OF COVID-19 IMPACT ON THE ECONOMIC SCENARIO IN THE DIGITAL DIABETES MANAGEMENT MARKET

6 DIGITAL DIABETES MANAGEMENT MARKET,  BY PRODUCT & SERVICE (Page No. - 80)
    6.1 INTRODUCTION
           TABLE 17 DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
    6.2 DEVICES
           TABLE 18 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
           TABLE 19 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           6.2.1 SMART GLUCOSE METERS
                    6.2.1.1 Reducing prices and technological innovations to drive segment growth
                               TABLE 20 KEY SMART GLUCOSE METERS AVAILABLE IN THE MARKET
                               TABLE 21 SMART GLUCOSE METERS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 CONTINUOUS GLUCOSE MONITORING SYSTEMS
                    6.2.2.1 CGM segment to grow at the highest CAGR during the forecast period
                               TABLE 22 KEY CGM SYSTEMS AVAILABLE IN THE MARKET
                               TABLE 23 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           6.2.3 SMART INSULIN PENS
                    6.2.3.1 Increasing demand for personalized or patient-centric devices without needle-stick injuries to drive segment growth
                               TABLE 24 KEY SMART INSULIN PENS AVAILABLE IN THE MARKET
                               TABLE 25 SMART INSULIN PENS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.4 SMART INSULIN PUMPS/CLOSED-LOOP SYSTEMS & SMART INSULIN PATCHES
                    6.2.4.1 Benefits of smart insulin pumps and closed-loop systems to drive segment growth
                               TABLE 26 KEY SMART INSULIN PUMPS/CLOSED-LOOP SYSTEMS & SMART INSULIN PATCHES AVAILABLE IN THE MARKET
                               TABLE 27 SMART INSULIN PUMPS/CLOSED-LOOP SYSTEMS & SMART INSULIN PATCHES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 DIGITAL DIABETES MANAGEMENT APPS
           TABLE 28 DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
           TABLE 29 DIGITAL DIABETES MANAGEMENT APPS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.3.1 DIABETES & BLOOD GLUCOSE TRACKING APPS
                    6.3.1.1 Growing adoption of connected devices to drive segment growth
                               TABLE 30 KEY DIABETES & BLOOD GLUCOSE TRACKING APPS AVAILABLE IN THE MARKET
                               TABLE 31 DIABETES & BLOOD GLUCOSE TRACKING APPS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           6.3.2 WEIGHT & DIET MANAGEMENT APPS
                    6.3.2.1 Growing obese population and the increasing need to prevent diabetes to drive segment growth
                               TABLE 32 KEY WEIGHT & DIET MANAGEMENT APPS AVAILABLE IN THE MARKET
                               TABLE 33 WEIGHT & DIET MANAGEMENT APPS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 DATA MANAGEMENT SOFTWARE & PLATFORMS
           6.4.1 GROWING DEMAND FOR DIABETES DATA MANAGEMENT TO DRIVE SEGMENT GROWTH
                    TABLE 34 KEY DATA MANAGEMENT SOFTWARE & PLATFORMS AVAILABLE IN THE MARKET
                    TABLE 35 DATA MANAGEMENT SOFTWARE & PLATFORMS MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
    6.5 SERVICES
           6.5.1 INCREASING ADOPTION OF REMOTE ONLINE COACHING SERVICES AMONG DIABETES PATIENTS TO DRIVE SEGMENT GROWTH
                    TABLE 36 KEY SERVICES AVAILABLE IN THE MARKET
                    TABLE 37 DIGITAL DIABETES MANAGEMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE (Page No. - 101)
    7.1 INTRODUCTION
           TABLE 38 DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
    7.2 WEARABLE DEVICES
           7.2.1 WEARABLE DEVICES DOMINATE THE DIGITAL DIABETES MANAGEMENT DEVICES MARKET
                    TABLE 39 WEARABLE DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
    7.3 HANDHELD DEVICES
           7.3.1 INCREASING DEMAND FOR REMOTE MONITORING TO BOOST SEGMENT GROWTH
                    TABLE 40 HANDHELD DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY COUNTRY,  2020–2027 (USD MILLION)

8 DIGITAL DIABETES MANAGEMENT MARKET, BY END USER (Page No. - 105)
    8.1 INTRODUCTION
           TABLE 41 DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 SELF/HOME HEALTHCARE
           8.2.1 HIGH COST OF INPATIENT CARE HAS FUELED THE PREFERENCE FOR SELF/HOME CARE
                    TABLE 42 DIGITAL DIABETES MANAGEMENT MARKET FOR SELF/HOME HEALTHCARE, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 HOSPITALS & SPECIALTY DIABETES CLINICS
           8.3.1 RISING DEMAND FOR POC TESTING IN HOSPITALS TO BOOST SEGMENT GROWTH
                    TABLE 43 DIGITAL DIABETES MANAGEMENT MARKET FOR HOSPITALS & SPECIALTY DIABETES CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
    8.4 ACADEMIC & RESEARCH INSTITUTES
           8.4.1 PRODUCT INNOVATION FOR DIABETES MANAGEMENT TO DRIVE SEGMENT GROWTH
                    TABLE 44 DIGITAL DIABETES MANAGEMENT MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2020–2027 (USD MILLION)

9 DIGITAL DIABETES MANAGEMENT MARKET, BY REGION (Page No. - 110)
    9.1 INTRODUCTION
           FIGURE 32 GEOGRAPHIC SNAPSHOT: MARKETS IN ASIA PACIFIC ARE EMERGING HOTSPOTS
           TABLE 45 DIGITAL DIABETES MANAGEMENT MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 33 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT MARKET SNAPSHOT
           TABLE 46 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           TABLE 47 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
           TABLE 48 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
           TABLE 49 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 50 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 51 NORTH AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Increasing diabetes prevalence and high penetration of digital platforms have boosted the growth of the US market
                               TABLE 52 US: MACROECONOMIC INDICATORS
                               TABLE 53 US: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 54 US: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 55 US: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 56 US: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 57 US: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Favorable reimbursement scenario has contributed to the use of digital diabetes management in Canada
                               TABLE 58 CANADA: MACROECONOMIC INDICATORS
                               TABLE 59 CANADA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 60 CANADA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 61 CANADA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 62 CANADA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 63 CANADA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.3 EUROPE
           FIGURE 34 EUROPE: DIGITAL DIABETES MANAGEMENT MARKET SNAPSHOT
           TABLE 64 EUROPE: DIGITAL DIABETES MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 65 EUROPE: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
           TABLE 66 EUROPE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
           TABLE 67 EUROPE: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 68 EUROPE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 69 EUROPE: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany accounted for the largest share of the European digital diabetes management market in 2021
                               TABLE 70 GERMANY: MACROECONOMIC INDICATORS
                               TABLE 71 GERMANY: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 72 GERMANY: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
                               TABLE 73 GERMANY: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 74 GERMANY: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 75 GERMANY: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Supportive government initiatives have contributed to the growth of the UK market
                               TABLE 76 UK: MACROECONOMIC INDICATORS
                               TABLE 77 UK: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 78 UK: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 79 UK: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 80 UK: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 81 UK: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Affordability of healthcare in France has contributed to the adoption of digital solutions
                               TABLE 82 FRANCE: MACROECONOMIC INDICATORS
                               TABLE 83 FRANCE: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 84 FRANCE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 85 FRANCE: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 86 FRANCE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 87 FRANCE: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing prevalence of diabetes to provide growth opportunities for market players in Italy
                               TABLE 88 ITALY: MACROECONOMIC INDICATORS
                               TABLE 89 ITALY: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 90 ITALY: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 91 ITALY: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 92 ITALY: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 93 ITALY: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Growing healthcare budget and rising efforts for boosting the local manufacturing of medical products to drive market growth
                               TABLE 94 SPAIN: MACROECONOMIC INDICATORS
                               TABLE 95 SPAIN: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 96 SPAIN: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 97 SPAIN: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 98 SPAIN: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 99 SPAIN: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 100 ROE: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                    TABLE 101 ROE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                    TABLE 102 ROE: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                    TABLE 103 ROE: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 104 ROE: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 35 ASIA PACIFIC: DIGITAL DIABETES MANAGEMENT MARKET SNAPSHOT
           TABLE 105 APAC: DIGITAL DIABETES MANAGEMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           TABLE 106 APAC: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
           TABLE 107 APAC: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
           TABLE 108 APAC: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 109 APAC: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 110 APAC: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 High acceptance of digital solutions for diabetes management driving market growth in Japan
                               TABLE 111 JAPAN: MACROECONOMIC INDICATORS
                               TABLE 112 JAPAN: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 113 JAPAN: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 114 JAPAN: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 115 JAPAN: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 116 JAPAN: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 Rising awareness about self-diabetes management among geriatric population driving market growth in China
                               TABLE 117 CHINA: MACROECONOMIC INDICATORS
                               TABLE 118 CHINA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 119 CHINA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 120 CHINA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 121 CHINA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 122 CHINA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growing burden of diabetes and increasing need to reduce rising healthcare costs have boosted the adoption of digital platforms
                               TABLE 123 INDIA: MACROECONOMIC INDICATORS
                               TABLE 124 INDIA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 125 INDIA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 126 INDIA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 127 INDIA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 128 INDIA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Initiatives to help treat or manage diabetes-related problems to drive market growth in Australia
                               TABLE 129 AUSTRALIA: MACROECONOMIC INDICATORS
                               TABLE 130 AUSTRALIA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 131 AUSTRALIA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
                               TABLE 132 AUSTRALIA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 133 AUSTRALIA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 134 AUSTRALIA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.4.5 REST OF ASIA PACIFIC
                    TABLE 135 ROAPAC: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                    TABLE 136 ROAPAC: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                    TABLE 137 ROAPAC: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 138 ROAPAC: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                    TABLE 139 ROAPAC: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 140 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY COUNTRY,  2020–2027 (USD MILLION)
           TABLE 141 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
           TABLE 142 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
           TABLE 143 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 144 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
           TABLE 145 LATIN AMERICA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 High private healthcare expenditure and increasing geriatric population driving market growth in Brazil
                               TABLE 146 BRAZIL: MACROECONOMIC INDICATORS
                               TABLE 147 BRAZIL: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 148 BRAZIL: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 149 BRAZIL: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 150 BRAZIL: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 151 BRAZIL: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Growing obesity rate in Mexico to drive market growth
                               TABLE 152 MEXICO: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                               TABLE 153 MEXICO: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                               TABLE 154 MEXICO: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                               TABLE 155 MEXICO: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                               TABLE 156 MEXICO: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 157 ROLATAM: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                    TABLE 158 ROLATAM: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE, 2020–2027 (USD MILLION)
                    TABLE 159 ROLATAM: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE,  2020–2027 (USD MILLION)
                    TABLE 160 ROLATAM: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE,  2020–2027 (USD MILLION)
                    TABLE 161 ROLATAM: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER,  2020–2027 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 DIGITIZATION OF HEALTH SYSTEMS IN AFRICAN COUNTRIES HAS YET TO PICK UP PACE
                    TABLE 162 AFRICA: MACROECONOMIC INDICATORS
                    TABLE 163 MEA: DIGITAL DIABETES MANAGEMENT MARKET, BY PRODUCT & SERVICE,  2020–2027 (USD MILLION)
                    TABLE 164 MEA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY PRODUCT TYPE,  2020–2027 (USD MILLION)
                    TABLE 165 MEA: DIGITAL DIABETES MANAGEMENT APPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 166 MEA: DIGITAL DIABETES MANAGEMENT DEVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 167 MEA: DIGITAL DIABETES MANAGEMENT MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 167)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
               FIGURE 36 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE DIGITAL DIABETES MANAGEMENT MARKET
     10.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN THE DIGITAL DIABETES MANAGEMENT MARKET
               FIGURE 37 REVENUE SHARE ANALYSIS OF KEY PLAYERS OPERATING IN THE DIGITAL DIABETES MANAGEMENT MARKET
     10.4 MARKET SHARE ANALYSIS
               FIGURE 38 MARKET SHARE ANALYSIS: CONTINUOUS GLUCOSE MONITORING DEVICES (2021)
               FIGURE 39 MARKET SHARE ANALYSIS: INSULIN PUMPS MARKET (2021)
               FIGURE 40 MARKET SHARE ANALYSIS: SMART INSULIN PENS MARKET (2021)
               FIGURE 41 MARKET SHARE ANALYSIS: DIABETES APPS MARKET (2021)
     10.5 R&D ASSESSMENT OF KEY PLAYERS
               FIGURE 42 R&D EXPENDITURE: KEY PLAYERS IN THE DIGITAL DIABETES MANAGEMENT MARKET, 2019, 2020, AND 2021
     10.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
               FIGURE 43 GEOGRAPHIC REVENUE ASSESSMENT: DIGITAL DIABETES MANAGEMENT MARKET (2021)
     10.7 COMPANY EVALUATION QUADRANT
               FIGURE 44 DIGITAL DIABETES MANAGEMENT MARKET: COMPANY EVALUATION MATRIX, 2021
             10.7.1 STARS
             10.7.2 EMERGING LEADERS
             10.7.3 PERVASIVE PLAYERS
             10.7.4 PARTICIPANTS
     10.8 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS
               FIGURE 45 DIGITAL DIABETES MANAGEMENT MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS
             10.8.1 PROGRESSIVE COMPANIES
             10.8.2 DYNAMIC COMPANIES
             10.8.3 STARTING BLOCKS
             10.8.4 RESPONSIVE COMPANIES
     10.9 COMPETITIVE BENCHMARKING
             10.9.1 OVERALL COMPANY FOOTPRINT
                       TABLE 168 OVERALL COMPANY FOOTPRINT (25 COMPANIES)
                       TABLE 169 COMPANY FOOTPRINT: BY PRODUCT & SERVICE (25 COMPANIES)
                       TABLE 170 COMPANY FOOTPRINT: BY DEVICE TYPE (25 COMPANIES)
                       TABLE 171 COMPANY FOOTPRINT: BY END USER (25 COMPANIES)
                       TABLE 172 COMPANY FOOTPRINT: BY REGION (25 COMPANIES)
     10.10 COMPETITIVE SCENARIO
               10.10.1 PRODUCT LAUNCHES
                          TABLE 173 PRODUCT LAUNCHES (2020–2022)
               10.10.2 DEALS
                          TABLE 174 DEALS (2020–2021)

11 COMPANY PROFILES (Page No. - 184)
     11.1 KEY PLAYERS
(Business overview, Products & services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and competitive threats)*
             11.1.1 MEDTRONIC PLC
                       FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2021)
             11.1.2 F. HOFFMANN-LA ROCHE
                       TABLE 176 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
                       FIGURE 47 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
             11.1.3 DEXCOM, INC.
                       TABLE 177 DEXCOM, INC.: BUSINESS OVERVIEW
                       FIGURE 48 DEXCOM, INC.: COMPANY SNAPSHOT (2021)
             11.1.4 ASCENSIA DIABETES CARE HOLDINGS AG
                       TABLE 178 ASCENSIA DIABETES CARE HOLDINGS AG: BUSINESS OVERVIEW
             11.1.5 ABBOTT LABORATORIES
                       TABLE 179 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                       FIGURE 49 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             11.1.6 B. BRAUN MELSUNGEN AG
                       TABLE 180 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                       FIGURE 50 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2021)
             11.1.7 TIDEPOOL
                       TABLE 181 TIDEPOOL: BUSINESS OVERVIEW
             11.1.8 GLOOKO, INC.
                       TABLE 182 GLOOKO: BUSINESS OVERVIEW
             11.1.9 LIFESCAN, INC.
                       TABLE 183 LIFESCAN, INC.: BUSINESS OVERVIEW
             11.1.10 AGAMATRIX, INC.
                       TABLE 184 AGAMATRIX, INC.: BUSINESS OVERVIEW
             11.1.11 TANDEM DIABETES CARE, INC.
                       TABLE 185 TANDEM DIABETES CARE: BUSINESS OVERVIEW
                       FIGURE 51 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2021)
             11.1.12 INSULET CORPORATION
                       TABLE 186 INSULET CORPORATION: BUSINESS OVERVIEW
                       FIGURE 52 INSULET CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.13 DARIOHEALTH CORPORATION
                       TABLE 187 DARIOHEALTH CORPORATION: BUSINESS OVERVIEW
                       FIGURE 53 DARIOHEALTH CORPORATION: COMPANY SNAPSHOT (2021)
             11.1.14 ONE DROP
                       TABLE 188 ONE DROP: BUSINESS OVERVIEW
             11.1.15 DOTTLI
                       TABLE 189 DOTTLI: BUSINESS OVERVIEW
             11.1.16 YPSOMED HOLDING AG
                       TABLE 190 YPSOMED HOLDING AG: BUSINESS OVERVIEW
                       FIGURE 54 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2021)
             11.1.17 ARKRAY, INC.
                       TABLE 191 ARKRAY, INC.: BUSINESS OVERVIEW
             11.1.18 ACON LABORATORIES, INC.
                       TABLE 192 ACON LABORATORIES, INC.: BUSINESS OVERVIEW
             11.1.19 CARE INNOVATIONS, LLC
                       TABLE 193 CARE INNOVATIONS, LLC: BUSINESS OVERVIEW
             11.1.20 HEALTH2SYNC
                       TABLE 194 HEALTH2SYNC: BUSINESS OVERVIEW
             11.1.21 EMPERRA GMBH E-HEALTH TECHNOLOGIES
                       TABLE 195 EMPERRA GMBH E-HEALTH TECHNOLOGIES: BUSINESS OVERVIEW
             11.1.22 AZUMIO
                       TABLE 196 AZUMIO: BUSINESS OVERVIEW
             11.1.23 DECIDE CLINICAL SOFTWARE GMBH
                       TABLE 197 DECIDE CLINICAL SOFTWARE GMBH: BUSINESS OVERVIEW
             11.1.24 PENDIQ GMBH
                       TABLE 198 PENDIQ GMBH: BUSINESS OVERVIEW
             11.1.25 BEATO
                       TABLE 199 BEATO: BUSINESS OVERVIEW

*Details on Business overview, Products & services offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and competitive threats might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 227)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major approaches in estimating the current digital diabetes management market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

This research study involved the widespread usage of secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the digital diabetes management market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the digital diabetes management market. Primary sources from the demand side include industry experts such as home healthcare providers, healthcare professionals, diabetes patients, payers, researchers, endocrinologists, and other related key opinion leaders.

Market Size Estimation

The total size of the digital diabetes management market was arrived at after data triangulation from four different approaches, as mentioned below. The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product, type, end user, and region).

Bottom-up Approach: Revenues of individual companies were gathered from public sources and databases. Shares of the digital diabetes management businesses of leading players were gathered from secondary sources to the extent available. In certain cases, the share of the business unit was ascertained after a detailed analysis of various parameters, including product portfolio, market positioning, selling price, and geographic reach and strength. Individual shares or revenue estimates were validated through expert interviews.

Country level Analysis: The size of the digital diabetes management market was obtained from the annual presentations of leading players and secondary data available in the public domain. The share of products and services in the overall digital diabetes management market was obtained from secondary data and validated by primary participants to arrive at the total digital diabetes management market. Primary participants further validated the numbers.

Primary Interviews: As a part of the primary research process, individual respondent insights on the market size and growth were taken during the interview (regional and global, as applicable). All the responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Geographic market assessment (by region & country): The geographic assessment was done using the following approaches:

Approach 1: Geographic revenue contributions/splits of leading players in the market (wherever available) and respective growth trends
Approach 2: Geographic adoption trends for individual product segments by end users and growth prospects for each of the segments (assumptions and indicative estimates validated from primary interviews)

At each point, the assumptions and approaches were validated through industry experts contacted during primary research. Considering the limitations of data available from secondary research, revenue estimates for individual companies (for the overall digital diabetes management market and geographic market assessment) were ascertained based on a detailed analysis of their respective product offerings, geographic reach/strength (direct or through distributors or suppliers), and the shares of the leading players in a particular region or country.

Rotator Cuff Injury Treatment  Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable.

Approach to derive the market size and estimate market growth

The market rankings for leading players were ascertained after a detailed assessment of their revenues from the digital diabetes management business using secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases, the revenue share was arrived at after a detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with industry experts.

Objectives of the Study

  • To define, describe, analyze, and forecast the digital diabetes management market by product, type, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the digital diabetes management market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To strategically profile key players in the global digital diabetes management market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, agreements, and other developments of leading players in the global digital diabetes management market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Europe digital diabetes management market into the Netherlands, Austria, Belgium, and others
  • Further breakdown of the Rest of Asia Pacific digital diabetes management market into Singapore, Malaysia, and others

Company Information

  • Detailed analysis and profiling of additional market players
Report Code
MD 6871
Published ON
Apr, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Digital Diabetes Management Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved